AN2 Therapeutics Insider Filing Shows 11.9K Share Board Grant
Rhea-AI Filing Summary
AN2 Therapeutics, Inc. (ANTX) filed a Form 4 reporting a routine equity grant to director Kabeer Aziz. On 07/10/2025 Mr. Aziz received 11,875 shares of common stock issued in lieu of cash compensation under the company’s non-employee director compensation policy. Because the award was compensation, the shares were priced at $0.00 and vested immediately.
Following the grant, Mr. Aziz now directly holds 30,552 shares. He also has indirect beneficial ownership—through Adjuvant Global Health Technology Fund, L.P. (1,995,958 shares) and Adjuvant Global Health Technology Fund DE, L.P. (377,542 shares)—bringing total reported influence to roughly 2.404 million shares. However, the filing notes that voting and dispositive power is shared with the funds’ general partners and that beneficial ownership is disclaimed except for pecuniary interest.
No derivative securities, options, sales, or open-market purchases were reported, and no cash was exchanged. The transaction appears purely compensatory and does not signal a deliberate insider buy or sell decision. Investors typically view such awards as neutral unless the size represents a material percentage of total shares outstanding, which the filing does not disclose.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine director stock grant; neutral market impact.
The 11,875-share award is standard non-cash board compensation, immediately vested and priced at zero. While it raises Aziz’s direct stake by ~64%, the absolute number is small relative to the >2 million shares he already influences via Adjuvant funds. No insider buying signal, no sale pressure, and no derivatives were involved. I classify the filing as not impactful for valuation or sentiment.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 11,875 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately. Shares are held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Shares are held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.
